Login to Your Account

FDA Panel Backs EGFR Drug From AstraZeneca For NSCLC

By Kim Coghill

Wednesday, September 25, 2002
SILVER SPRING, Md. - An FDA advisory panel provided late-stage lung cancer patients with a ray of hope Tuesday when it leaned toward recommending approval of Iressa, an epidermal growth factor receptor tyrosine kinase inhibitor. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription